Arizona Becton, Dickinson and Co. is planning to construct a medical products final-stage manufacturing and sterilization facility on a 32-acre site in Tucson. The project scope includes construction of a 120,000-sq-ft building with cold storage space; installation of fabrication, machining, tooling, assembly, sterilization and packaging equipment; and purchase and installation of supporting equipment. Primus Builders Inc. has been selected to provide design-build services for the project. Construction is expected to begin late in the third quarter of 2021. The estimated EPC cost is $65 million. Becton, Dickinson and Co., 1 Becton Drive, Franklin Lakes, N.J. 07417. IR#AZ210404.
California American Biodiesel Inc., doing business as Community Fuels, is planning to expand its biofuel terminal at the Port of Stockton. The two-phase project scope includes demolition and removal of some existing equipment; modification of existing equipment; construction of equipment foundations; purchase and erection of structural steel and biofuel storage tanks; and purchase and installation of biofuel pumps, heat exchangers, process piping and flow control and electrical distribution equipment. The project will increase storage capacity to 200 million gallons of renewable diesel and biodiesel blends from 85 million gallons. The company is performing design engineering in-house for the project. Construction is expected to begin in mid-to-late 2021. The estimated EPC cost is $40 million. Community Fuels, 809-C Snedeker Ave., Stockton, 95203. IR#CA210409.
Maryland TCR² Therapeutics Inc. is planning to establish a biopharmaceutical manufacturing plant in Rockville. The project scope includes fit-out of clean rooms and purchase and installation of stainless steel piping, freezers, fume hoods, bioreactors and wet laboratory, filtration, sterile filling, testing, air handling, sterilization, labeling and packaging equipment. Equipment will be installed in an existing 85,000-sq-ft leased building. A project schedule is being developed; commercial-scale production is expected to begin in 2023. TCR² will use the facility to produce disruptive cellular therapies for the treatment of solid tumors and hematologic cancers. The estimated EPC cost is between $25 million and $30 million. TCR² Therapeutics Inc., 100 Binney St., Cambridge, Mass. 02142. IR#MD210309.
Information is derived from Industrial Reports, a market intelligence firm specializing in industrial construction. To receive the full report with details and contacts for any of the above projects, call 800-235-2330 x2002 or email ENRprojects@industrialreports.com. To see all recent projects or to receive new project alerts, go to: http://www.industrialreports.com/enr.
